



## Innovative Design of Both Dressing and Primary Packaging Can Simplify Chronic Wound Management

Caillava Celine<sup>1</sup>, Geri Chloe<sup>2</sup>, Kurkdjian Emilie<sup>1</sup>, Guillemin Yannis<sup>1</sup> and Gouze Jean Noel<sup>1\*</sup>

<sup>1</sup>Department of Research and Development, Genbiotech, France

<sup>2</sup>CICAT-Occitanie Wound Network, University Hospital of Montpellier, France

### Clinical Image

Time and cost associated to the care of chronic wound is a significant burden to both patients and the medical system [1-3]. GBT013, a biodegradable and microporous collagen-based dressing, was designed not only to address healing efficacy but also to simplify chronic wound management. It is used at the patient bedside with no need for operating rooms or staples. A single dressing is able to address multiple wounds of different sizes and forms following cut-off. The primary packaging serves as a container for dressing pre-use rehydration, which is required for a proper adherence within the wound bed (Figure 1). Optimization of the packaging minimizes manipulation by the physician and limits subsequent risk of contamination. Three applications have been sufficient to complete healing both in DFU and VLU clinical cases supporting GBT013 as an efficient and cost-effective treatment for chronic wound management (Figure 2) [4,5].

### OPEN ACCESS

#### \*Correspondence:

Gouze Jean Noel, Department of Research and Development, Genbiotech, 280 rue de Goa, Antibes, 06600, France,

E-mail: [jngouze@genbiotech.com](mailto:jngouze@genbiotech.com)

Received Date: 13 Feb 2019


Accepted Date: 19 Mar 2019

Published Date: 21 Mar 2019


#### Citation:

Caillava C, Geri C, Kurkdjian E, Guillemin Y, Gouze JN. Innovative Design of Both Dressing and Primary Packaging Can Simplify Chronic Wound Management. *J Surg Tech Proced.* 2019; 3(1): 1024.

Copyright © 2019 Gouze Jean Noel. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



**Figure 1:** A,B). GBT013 is a sterile collagen based dressing presented in a sterile plastic blister. C,D). Hydration of GBT013 is performed during a few minutes directly in the primary packaging using saline solution. E). GBT013 can be handled at the patient bedside using sterile forceps. F). Hydrated GBT013 is applied directly to the wound bed and layered if further applications are needed.



**Figure 2:** Venous leg ulcer with arterial origin, 9 months duration. GBT013 treatment consisted in one application during 7.7 weeks follow-up.

### References

1. Falanga V. Care of venous leg ulcers. *Ostomy Wound Manage.* 1999;45(1):33-43.
2. Hansson C, Andersson E, Swanbeck G. A follow-up study of leg and foot ulcer patients. *Acta Derm Venereol.* 1987;67(6):496-500.
3. Olin JW, Beusterien KM, Childs MB, Seavey C, McHugh L, Griffiths RI. Medical costs of treating venous stasis ulcers: evidence from a retrospective cohort study. *Vasc Med.* 1999;4(1):1-7.

4. Dumont I, Lepeut M, Segalen C, Guillemin Y, Gouze JN. Use of GBT013, a collagen-based dressing, for the healing of diabetic foot ulcers: a case series. *Journal of the American Podiatric Medical Association*. In press. 2018.
5. Dumont I, Caillava C, Dupoirion S, Guillemin Y, Gouze JN. Complete healing of venous leg ulcer using a collagen based dressing : a case report. *J Surg Tech Proced*. 2018;2(2):1-3.